Survival of patients with MRC intermediate-risk cytogenetics according to age group and DNMT3A and NPM1 mutation status. (A) OS for MRC intermediate-risk patients aged <60 years or (B) aged ≥60 years, stratified according to DNMT3A mutation status. (C) OS for MRC intermediate-risk patients aged <60 years or (D) aged ≥60 years, stratified according to NPM1 mutation status. (E) OS for MRC intermediate-risk patients aged <60 years or (F) aged ≥60 years, stratified according to DNMT3A and NPM1 mutation status. P values in (A-D) were calculated from univariate Cox proportional hazards models, and in (E) and (F) from bivariate models, using the Wald test. All models were stratified for treatment arm. mut, mutated; wt, wild-type.